EuroBiotech Report—Autolus delay, Novartis sale, Sonnet deal, Y-mAbs and the U.K.

Map of Europe

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week at Autolus, which revealed a manufacturing delay is holding up multiple CAR-T clinical development programs. Elsewhere, Novartis licensed late-phase rare genetic disease treatment leniolisib to Pharming. Sonnet BioTherapeutics picked up an experimental treatment for chemotherapy-induced peripheral neuropathy that was once in Merck KGaA's pipeline. Y-mAbs Therapeutics revealed the extent of its hiring since last year's IPO. The U.K. made a pitch to attract the best of the world's scientists. And more. — Nick Taylor
1. Autolus delays multiple CAR-T clinical programs
A manufacturing delay is stymying progress of a clutch of Autolus’ CAR-T programs. Autolus revealed the setbacks alongside news that it is dumping the first-generation version of AUTO2 in the face of tough competition in the BCMA space.

2. Novartis sells phase 3 rare disease drug to Pharming

Pharming has licensed late-phase rare genetic disease treatment leniolisib from Novartis for $20 million (€17.9 million) upfront. The immunomodulator could come to market in activated PI3K-delta syndrome (APDS) in the second half of 2021. 
3. Sonnet bags ex-Serono neuropathy drug via Relief Therapeutics deal
Sonnet BioTherapeutics has struck a deal to acquire an ex-Serono drug from Relief Therapeutics. The agreement tees Sonnet up to advance the asset in chemotherapy-induced peripheral neuropathy (CIPN) using an equity facility worth up to $100 million (€89 million).


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

4. Y-mAbs ramps up headcount in post-IPO hiring spree

Y-mAbs Therapeutics has rapidly expanded its headcount by 65%. The post-IPO hiring spree comes as Y-mAbs heads toward FDA filings of two cancer drugs later this year.
5. U.K. plans post-Brexit easing of rules on migrant scientists
The U.K. is set to open its doors to top scientists in a bid to retain and strengthen its leading position in the field after Brexit. Through a series of reforms, U.K. Prime Minister Boris Johnson aims to create a fast-track immigration route that facilitates the flow of talent from around the world. 

And more articles of note>>    

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.